Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new NYC study finds that fewer than 1 in 10 people on HIV PrEP also received doxy-PEP — an antibiotic that can significantly cut STI risk. Black patients and those in high-poverty neighborhoods were the least likely to get it. Researchers say the same racial and socioeconomic gaps seen with PrEP are already emerging with doxy-PEP, just one year after NYC began recommending it.
A study presented at IDWeek reveals a troubling gap in STI prevention: despite being in a high-risk group, fewer than 1 in 10 people taking HIV pre-exposure prophylaxis (PrEP) in New York City also received doxycycline post-exposure prophylaxis (doxy-PEP) — an antibiotic taken within 72 hours of unprotected sex that can significantly reduce the risk of certain STIs.
The findings are especially concerning because racial and socioeconomic disparities emerged almost immediately. Black patients and those living in high-poverty neighborhoods were significantly less likely to receive doxy-PEP prescriptions, mirroring the same inequities that plagued HIV PrEP rollout over a decade ago. Researchers say the pattern appeared within just one year of NYC's 2023 recommendation — and they're hoping to intervene faster this time.
By the Numbers:
Why it matters: Doxy-PEP is a proven, low-cost tool to curb bacterial STIs — but only if people can access it. Closing these early-emerging disparities through clinician education and targeted outreach could prevent the same years-long equity gaps that have defined HIV PrEP access.